These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 38860864)

  • 41. High Pretreatment Platelet-to-Albumin Ratio Predicts Poor Survival Results in Locally Advanced Nasopharyngeal Cancers Treated with Chemoradiotherapy.
    Haksoyler V; Topkan E
    Ther Clin Risk Manag; 2021; 17():691-700. PubMed ID: 34262282
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers.
    Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH
    Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Age is a significant biomarker for the selection of neoadjuvant chemotherapy plus radiotherapy versus concurrent chemoradiotherapy in patients with advanced nasopharyngeal carcinoma.
    Lin Y; Yu X; Lu L; Chen H; Wu J; Chen Y; Lin Q; Wang X; Chen X; Chen X
    Cancer Biomark; 2023; 37(1):1-11. PubMed ID: 36938724
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Serum miRNAs, a potential prognosis marker of loco-regionally advanced nasopharyngeal carcinoma patients treated with CCRT.
    Zhang Z; Huang J; Wang G; Jin F; Zheng J; Xiao H; Lei L; Luo J; Chen C
    BMC Cancer; 2020 Mar; 20(1):183. PubMed ID: 32131777
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
    Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of concurrent chemoradiotherapy plus Endostar compared with concurrent chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma: a retrospective study.
    Yin Y; Zhou Z; Li Z; Shen M; Qin Y; Yang C; Wang R; Kang M
    Radiat Oncol; 2022 Jul; 17(1):135. PubMed ID: 35906636
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Nomogram to Identify the Optimal Candidates for Induction Chemotherapy in Advanced N-Stage Nasopharyngeal Carcinoma.
    Jiang YT; Chen KH; Liang ZG; Yang J; Qu S; Li L; Zhu XD
    Cancer Manag Res; 2022; 14():2583-2596. PubMed ID: 36068822
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Home enteral nutrition may prevent myelosuppression of patients with nasopharyngeal carcinoma treated by concurrent chemoradiotherapy.
    Li X; Zhou J; Chu C; You Q; Zhong R; Rao Z; Hu W
    Head Neck; 2019 Oct; 41(10):3525-3534. PubMed ID: 31301097
    [TBL] [Abstract][Full Text] [Related]  

  • 49. MRI-based clinical radiomics nomogram may predict the early response after concurrent chemoradiotherapy in locally advanced nasopharyngeal carcinoma.
    Wu M; Xu W; Fei Y; Li Y; Yuan J; Qiu L; Zhang Y; Chen G; Cheng Y; Cao Y; Sun X; Zhou S
    Front Oncol; 2023; 13():1192953. PubMed ID: 37256173
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A deep learning-based radiomic nomogram for prognosis and treatment decision in advanced nasopharyngeal carcinoma: A multicentre study.
    Zhong L; Dong D; Fang X; Zhang F; Zhang N; Zhang L; Fang M; Jiang W; Liang S; Li C; Liu Y; Zhao X; Cao R; Shan H; Hu Z; Ma J; Tang L; Tian J
    EBioMedicine; 2021 Aug; 70():103522. PubMed ID: 34391094
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of concurrent chemoradiotherapy versus induction chemotherapy followed by radiation in patients with nasopharyngeal carcinoma.
    Komatsu M; Tsukuda M; Matsuda H; Horiuchi C; Taguch T; Takahashi M; Nishimura G; Mori M; Niho T; Ishitoya J; Sakuma Y; Hirama M; Shiono O
    Anticancer Res; 2012 Feb; 32(2):681-6. PubMed ID: 22287763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis.
    Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T
    Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction Chemotherapy plus Concurrent Chemoradiotherapy vs Concurrent Chemoradiotherapy in Elderly Patients with Advanced Nasopharyngeal Carcinoma.
    Wang C; Tang X; Wang J; Song J; Xu Y
    Otolaryngol Head Neck Surg; 2017 Aug; 157(2):233-238. PubMed ID: 28418781
    [TBL] [Abstract][Full Text] [Related]  

  • 54. High pretreatment systemic immune-inflammation index values are associated with diminished short-term success after temporomandibular joint arthrocentesis procedure.
    Somay E; Yilmaz B
    BMC Oral Health; 2021 Oct; 21(1):531. PubMed ID: 34654426
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concurrent chemoradiotherapy with/without induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: Long-term results of phase 3 randomized controlled trial.
    Li WF; Chen NY; Zhang N; Hu GQ; Xie FY; Sun Y; Chen XZ; Li JG; Zhu XD; Hu CS; Xu XY; Chen YY; Hu WH; Guo L; Mo HY; Chen L; Mao YP; Sun R; Ai P; Liang SB; Long GX; Zheng BM; Feng XL; Gong XC; Li L; Shen CY; Xu JY; Guo Y; Chen YM; Zhang F; Lin L; Tang LL; Liu MZ; Ma J; Sun Y
    Int J Cancer; 2019 Jul; 145(1):295-305. PubMed ID: 30613964
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prognostic value of pretreatment prognostic nutritional index and lactated dehydrogenase in locally advanced nasopharyngeal carcinoma patients.
    Xiong Y; Shi LL; Zhu LS; Peng G
    Ann Palliat Med; 2021 Apr; 10(4):4122-4133. PubMed ID: 33832314
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis.
    Wang L; Wu Z; Xie D; Lv S; Xia L; Su Y
    Radiat Oncol; 2020 Jul; 15(1):160. PubMed ID: 32615984
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Significant survival benefit of adjuvant chemotherapy after concurrent chemoradiotherapy in locally advanced high-risk nasopharyngeal carcinoma.
    Liang ZG; Chen XQ; Lin GX; Yu BB; Chen KH; Zhong QL; Nong SK; Li L; Qu S; Su F; Zhao W; Li Y; Zhu XD
    Sci Rep; 2017 Feb; 7():41449. PubMed ID: 28150694
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Radiotherapy dose-volume parameters predict facial lymphedema after concurrent chemoradiation for nasopharyngeal carcinoma.
    Kim D; Nam J; Kim W; Park D; Joo J; Jeon H; Ki Y
    Radiat Oncol; 2021 Sep; 16(1):172. PubMed ID: 34488836
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Induction chemotherapy regimes in first-line treatment for locoregionally advanced nasopharyngeal carcinoma: A network meta-analysis and cost-effectiveness analysis.
    Xu W; Qiu L; Li F; Fei Y; Wei Q; Shi K; Zhu Y; Luo J; Wu M; Yuan J; Liu H; Mao J; Cao Y; Zhou S; Guan X
    Oral Oncol; 2024 Jul; 154():106865. PubMed ID: 38823173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.